Nektar Therapeutics (NASDAQ:NKTR) Q1 2021 Earnings Conference Call May 6, 2021 5:00 PM ET Company Participants Jennifer Ruddock - Head of Corporate Affairs Howard Robin - President and CEO Gil Labrucherie - COO and CFO Dr. Jonathan Zalevsky - Chief of Research and Development Dr. Brian Kotzin - Interim CMO and Head of Development Conference Call Participants Peter Lawson - Barclays Jay Olson - Oppenheimer Jessica Fye - JPMorgan Alex Bouilloux - Mizuho Ben Burnett - Stifel Daina Graybosch - SVB Leerink Arlin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2020 Earnings Conference Call February 25, 2021 5:00 PM ET Company Participants Jennifer Ruddock - Senior Vice President, Strategy and Corporate Affairs Howard Robin - President, Chief Executive Officer Jonathan Zalevsky - Chief Research & Development Officer Brian Kotzin - Interim Chief Medical Officer, Head of Development Gil Labrucherie - Chief Operating Officer, Chief Financial Officer Conference Call Participants Peter Lawson - Barclays Jay Olson - Oppenheimer Jessi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ Form 10-K ___________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to ...

NEKTAR® SMARTER MEDICINE™ 39th Annual J.P. Morgan Healthcare Conference Howard Robin President & CEO January 11, 2021 2 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start of and plans for ongoing or planned clinical trials with partners, the therapeutic potential of our drug candidates, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially, and these sta ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Jennifer Ruddock - SVP, Strategy & Corporate Affairs Howard Robin - CEO, President & Director Wei Lin - SVP & Head, Development Jonathan Zalevsky - Chief Research & Development Officer Gilbert Labrucherie - SVP, CFO & COO Conference Call Participants Alexander Duncan - Piper Sandler & Co. Daniel Wolle - JPMorgan Chase & Co. George Farmer - BMO Capital Markets Alexandre Bouilloux - Mizuho Secur ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 For the transition period from to Commission File Number: 0-24006 ______________________________________________________________ ...

Nektar Therapeutics (NASDAQ:NKTR) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Jennifer Ruddock - Senior Vice President, Strategy and Corporate Affairs Howard Robin - President and Chief Executive Officer Gil Labrucherie - Chief Operating Officer and Chief Financial Officer Jonathan Zalevsky - Chief, Research and Development Wei Lin - Head, Development Conference Call Participants Peter Lawson - Barclays Tyler Van Buren - Piper Sandler Chris Shibutani - Cowen Alex Lim - Mi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

Nektar Therapeutics (NASDAQ:NKTR) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Jennifer Ruddock - SVP, Strategy & Corporate Affairs Howard Robin - President & CEO Wei Lin - SVP & Head of Development Jonathan Zalevsky - Chief R&D Officer Gil Labrucherie - COO & CFO Conference Call Participants Peter Lawson - Barclays Tyler Van Buren - Piper Sandler Chris Shibutani - Cowen Difei Yang - Mizuho Bert Hazlett - BTIG George Farmer - BMO Capital Markets Arlinda Lee - Canaccord Aydin ...